Tests a new care plan with lung surgery for older lung cancer patients
Studies lung cancer surgery and recovery care in adults aged 65 and older.
Key facts
- Who runs it
- Peking University People's Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Aug 2024
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional, 3 groups
- Treatments tested
- Pulmonary Lobectomy plus Mediastinal Lymph Node Sampling
- Pulmonary Segmentectomy plus Mediastinal Lymph Node Sampling
- Pulmonary Wedge Resection plus Mediastinal Lymph Node Sampling
- Record updated
- 15 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 65 or older with confirmed non-small cell lung cancer who can have surgery to remove the tumour.
- Age
- 65 years or older
- Sex
- All sexes
- Disease stage
- Non-small cell lung cancer confirmed by tissue testing, at a clinical stage where surgery to remove the cancer is possible
Main reasons for not taking part
- Another cancer within the last 5 years
- Severe heart, liver, kidney or lung problems that make chest surgery unsafe
- Cancer that has spread to distant parts of the body and prevents complete removal
- Uncontrolled serious infection or clear blood clotting problems
- Severe mental illness or memory and thinking problems that prevent taking part in treatment and follow-up
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Aged ≥65 years old
- Pathologically confirmed non-small cell lung cancer with clinical stage eligible for curative surgical resection
- Complete preoperative geriatric comprehensive assessment data available
- Capable of finishing planned surgery and long-term follow-up
- Voluntarily sign informed consent form
Who cannot take part
- Preoperative confirmed distant metastasis preventing radical resection
- History of other malignant tumors within recent 5 years
- Severe organic dysfunction of heart, liver, renal or respiratory system that cannot tolerate thoracic surgery
- Uncontrolled active severe infection or obvious coagulation disorders
- Severe psychiatric disorder or cognitive dysfunction failing to cooperate with treatment and follow-up
- Refuse random grouping and postoperative regular monitoring
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Fan Yang, MDTaking people
About the trial
What the trial wants to find out
This multicenter prospective clinical study focuses on elderly patients with lung cancer. The investigators will build a standardized clinical registry database, develop perioperative risk stratification and surgical early-warning models, optimize individualized surgical regimens, construct multidisciplinary perioperative comprehensive therapy, integrated Chinese-Western medicine full-cycle management and personalized postoperative rehabilitation systems, so as to form a whole-process optimized treatment model for elderly lung cancer.
The 3 groups in the trial
- Lobectomy GroupTreatment being tested
Patients receive standard lobectomy plus mediastinal lymph node sampling for early-stage non-small cell lung cancer, for elderly patients ≥65 years with T1N0M0 tumor. Postoperative standard perioperative management and regular follow-up are conducted.
Treatment: Pulmonary Lobectomy plus Mediastinal Lymph Node Sampling
- Segmentectomy GroupTreatment being tested
Patients receive anatomic segmentectomy plus mediastinal lymph node sampling. All enrolled elderly patients are stratified by tumor size and preoperative geriatric risk score before randomization, followed by unified postoperative monitoring and adaptive perioperative treatment based on MRD and biomarker results.
Treatment: Pulmonary Segmentectomy plus Mediastinal Lymph Node Sampling
- Wedge Resection GroupTreatment being tested
Patients receive pulmonary wedge resection plus mediastinal lymph node sampling. After surgery, low-risk patients get de-escalated adaptive perioperative treatment guided by postoperative MRD surveillance, while high-risk patients receive individualized intensive comprehensive therapy.
Treatment: Pulmonary Wedge Resection plus Mediastinal Lymph Node Sampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter Clinical Study on a New Treatment Model Combining New Surgical Techniques, Perioperative Comprehensive Treatment, and Postoperative Rehabilitation for Elderly Patients With Lung Cancer
- Plain-language title
- Tests a new care plan with lung surgery for older lung cancer patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 15 July 2026